サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1411376

アンチセンスとRNAi治療薬市場：技術、用途、投与経路別-2024-2030年の世界予測

Antisense & RNAi Therapeutics Market by Technology (Antisense RNA, RNA Interference), Application (Cardiovascular Diseases (CVDs), Genetic Disorders, Infectious Diseases), Route of Administration - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 195 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
アンチセンスとRNAi治療薬市場：技術、用途、投与経路別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アンチセンスとRNAi治療薬市場規模は2023年に45億1,000万米ドルと推計され、2024年には49億3,000万米ドルに達し、CAGR 9.34%で2030年には84億3,000万米ドルに達すると予測されます。

アンチセンスとRNAi治療薬の世界市場

主な市場の統計
基準年[2023］ 45億1,000万米ドル
予測年[2024］ 49億3,000万米ドル
予測年 [2030] 84億3,000万米ドル
CAGR（%） 9.34%
Antisense &RNAi Therapeutics Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはアンチセンスとRNAi治療薬市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、アンチセンスとRNAi治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-アンチセンスとRNAi治療薬市場の市場規模および予測は？

2-アンチセンスとRNAi治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-アンチセンスとRNAi治療薬市場における技術動向と規制の枠組みは？

4-アンチセンスとRNAi治療薬市場における主要ベンダーの市場シェアは？

5-アンチセンスとRNAi治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界の高齢者人口の増加と慢性疾患の蔓延
      • 効果的で新しい治療法へのニーズの高まり
      • アンチセンスおよびRNAiベースの治療法に関する研究開発活動の増加
    • 抑制要因
      • アンチセンス RNAi治療薬の製造コストが高い
    • 機会
      • アンチセンス RNAi治療における臨床の進歩
      • アンチセンス RNAi治療薬の発見と開発への多額の投資
    • 課題
      • アンチセンス RNAi治療薬の有効性に関する懸念
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 アンチセンスとRNAi治療薬市場：技術別

  • アンチセンスRNA
  • RNA干渉
    • miRNA
    • siRNA

第7章 アンチセンスとRNAi治療薬市場：用途別

  • 心血管疾患（CVD）
  • 遺伝性疾患
  • 感染症
  • 神経変性疾患
  • 腫瘍学
  • 腎臓病
  • 呼吸器疾患

第8章 アンチセンスとRNAi治療薬市場：投与経路別

  • 皮内注射
  • 腹腔内注射
  • 静脈注射
  • 肺分娩
  • 話題の配信

第9章 南北アメリカのアンチセンスとRNAi治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域のアンチセンスとRNAi治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカのアンチセンスとRNAi治療薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Alnylam Pharmaceuticals, Inc.
    • Amarna Therapeutics BV
    • Arbutus Biopharma Corporation
    • Arrowhead Pharmaceuticals, Inc.
    • AstraZeneca plc
    • Axolabs GmbH
    • Benitec Biopharma Limited
    • BioNTech SE
    • Carisma Therapeutics Inc.
    • Dicerna Pharmaceuticals, Inc.
    • Evox Therapeutics Ltd
    • Exicure, Inc.
    • GenScript Biotech Corporation
    • InteRNA Technologies BV
    • Ionis Pharmaceuticals, Inc.
    • miRagen Therapeutics, Inc.
    • Regenxbio Inc.
    • RXi Pharmaceuticals Corporation
    • Sanofi S.A.
    • Silence Therapeutics plc
    • Sirnaomics, Inc.
    • Wave Life Sciences Ltd
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ANTISENSE & RNAI THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTISENSE & RNAI THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 8. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 12. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ANTISENSE & RNAI THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. ANTISENSE & RNAI THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTISENSE & RNAI THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE RNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 9. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MIRNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SIRNA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISEASES (CVDS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RENAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRA-DERMAL INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAPERITONEAL INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PULMONARY DELIVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL DELIVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RNA INTERFERENCE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. ANTISENSE & RNAI THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 194. ANTISENSE & RNAI THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. ANTISENSE & RNAI THERAPEUTICS MARKET LICENSE & PRICING
目次
Product Code: MRR-8E22B61932D4

[195 Pages Report] The Antisense & RNAi Therapeutics Market size was estimated at USD 4.51 billion in 2023 and expected to reach USD 4.93 billion in 2024, at a CAGR 9.34% to reach USD 8.43 billion by 2030.

Global Antisense & RNAi Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023] USD 4.51 billion
Estimated Year [2024] USD 4.93 billion
Forecast Year [2030] USD 8.43 billion
CAGR (%) 9.34%
Antisense & RNAi Therapeutics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antisense & RNAi Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antisense & RNAi Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antisense & RNAi Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Amarna Therapeutics BV, Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals, Inc., AstraZeneca plc, Axolabs GmbH, Benitec Biopharma Limited, BioNTech SE, Carisma Therapeutics Inc., Dicerna Pharmaceuticals, Inc., Evox Therapeutics Ltd, Exicure, Inc., GenScript Biotech Corporation, InteRNA Technologies BV, Ionis Pharmaceuticals, Inc., miRagen Therapeutics, Inc., Regenxbio Inc., RXi Pharmaceuticals Corporation, Sanofi S.A., Silence Therapeutics plc, Sirnaomics, Inc., and Wave Life Sciences Ltd.

Market Segmentation & Coverage

This research report categorizes the Antisense & RNAi Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Antisense RNA
    • RNA Interference
      • miRNA
      • siRNA
  • Application
    • Cardiovascular Diseases (CVDs)
    • Genetic Disorders
    • Infectious Diseases
    • Neurodegenerative Disorders
    • Oncology
    • Renal Diseases
    • Respiratory Disorders
  • Route of Administration
    • Intra-dermal Injections
    • Intraperitoneal Injections
    • Intravenous Injections
    • Pulmonary Delivery
    • Topical Delivery
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antisense & RNAi Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antisense & RNAi Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Antisense & RNAi Therapeutics Market?

4. What is the market share of the leading vendors in the Antisense & RNAi Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Antisense & RNAi Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Antisense & RNAi Therapeutics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in geriatric populations and prevalence of chronic diseases worldwide
      • 5.1.1.2. Growing need for effective and novel therapeutics
      • 5.1.1.3. Increase in R&D activities on antisense and RNAi-based therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of manufacturing antisense-RNAi-therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Clinical advancements in antisense-RNAi-therapeutics
      • 5.1.3.2. Significant investments in the discovery and development of antisense-RNAi-therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with the efficacy of antisense-RNAi-therapeutics
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Antisense & RNAi Therapeutics Market, by Technology

  • 6.1. Introduction
  • 6.2. Antisense RNA
  • 6.3. RNA Interference
    • 6.4.1. miRNA
    • 6.4.2. siRNA

7. Antisense & RNAi Therapeutics Market, by Application

  • 7.1. Introduction
  • 7.2. Cardiovascular Diseases (CVDs)
  • 7.3. Genetic Disorders
  • 7.4. Infectious Diseases
  • 7.5. Neurodegenerative Disorders
  • 7.6. Oncology
  • 7.7. Renal Diseases
  • 7.8. Respiratory Disorders

8. Antisense & RNAi Therapeutics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intra-dermal Injections
  • 8.3. Intraperitoneal Injections
  • 8.4. Intravenous Injections
  • 8.5. Pulmonary Delivery
  • 8.6. Topical Delivery

9. Americas Antisense & RNAi Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antisense & RNAi Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antisense & RNAi Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Alnylam Pharmaceuticals, Inc.
    • 13.1.2. Amarna Therapeutics BV
    • 13.1.3. Arbutus Biopharma Corporation
    • 13.1.4. Arrowhead Pharmaceuticals, Inc.
    • 13.1.5. AstraZeneca plc
    • 13.1.6. Axolabs GmbH
    • 13.1.7. Benitec Biopharma Limited
    • 13.1.8. BioNTech SE
    • 13.1.9. Carisma Therapeutics Inc.
    • 13.1.10. Dicerna Pharmaceuticals, Inc.
    • 13.1.11. Evox Therapeutics Ltd
    • 13.1.12. Exicure, Inc.
    • 13.1.13. GenScript Biotech Corporation
    • 13.1.14. InteRNA Technologies BV
    • 13.1.15. Ionis Pharmaceuticals, Inc.
    • 13.1.16. miRagen Therapeutics, Inc.
    • 13.1.17. Regenxbio Inc.
    • 13.1.18. RXi Pharmaceuticals Corporation
    • 13.1.19. Sanofi S.A.
    • 13.1.20. Silence Therapeutics plc
    • 13.1.21. Sirnaomics, Inc.
    • 13.1.22. Wave Life Sciences Ltd
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing